Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open-label, Dose-escalation Study to Evaluate the Safety and Pharmacokinetics (PK) of a Single Intravenous (IV) Infusion of TRP-8803 (psilocin) in Healthy Adult Participants

Trial Profile

A Phase 1, Open-label, Dose-escalation Study to Evaluate the Safety and Pharmacokinetics (PK) of a Single Intravenous (IV) Infusion of TRP-8803 (psilocin) in Healthy Adult Participants

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 12 Jan 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Psilocybin (Primary)
  • Indications Binge-eating disorder; Cancer; Complex regional pain syndromes; Fibromyalgia; Pain
  • Focus Adverse reactions

Most Recent Events

  • 12 Jan 2024 New trial record
  • 08 Jan 2024 According to a TRYP Therapeutics media release, achieving the three predetermined targets of psilocin blood levels in this study and confirming their safety will serve as the basis for dose selection in our planned Phase 2 studies with TRP-8803.
  • 08 Jan 2024 According to a TRYP Therapeutics media release, The Company has received approval from the Human Research Ethics Committee (HREC) in Australia to commence the groundbreaking Phase 1 clinical trial of TRP-8803 in healthy human volunteers.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top